Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists

PURPOSE: The prevalence of off-label anticancer drug use is not well characterized. The extent of off-label use is a policy concern because the clinical benefits of such use to patients may not outweigh costs or adverse health outcomes. METHODS: Prescribing data from IntrinsiQ Intellidose data syste...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Conti, Rena M., Bernstein, Arielle C., Villaflor, Victoria M., Schilsky, Richard L., Rosenthal, Meredith B., Bach, Peter B.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2013
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3595423/
https://ncbi.nlm.nih.gov/pubmed/23423747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.42.7252
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares